Anti-EV71 virus antibody and preparation method and application thereof
By screening and preparing spatial epitope antibodies against the EV71 viral VP1 protein, the problem of unclear side effects and neutralizing antibodies of the existing EV71 inactivated vaccine were solved, providing scientific basis and basis for EV71 specific antiviral drugs research, realizing Effective neutralization of EV71 virus.
Patent Information
- Application Number
- CN202210612129.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-05-27
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2042-05-27
AI Technical Summary
The existing EV71 inactivated vaccine has side effects and its changes and protective effects on neutralizing antibodies in the body are unclear. It is necessary to develop therapeutic neutralizing antibodies to cope with EV71 infection.
Screening was obtained for anti-EV71 virus antibodies with good specificity, and spatial epitope antibodies against EV71 virus VP1 protein. The preparation method includes inserting nucleic acid sequence into the expression vector and introducing it into the host cell for purification to obtain specific antibodies against EV71 virus.
It provides scientific basis for the study of EV71-specific antiviral drugs, lays the foundation for the study of humanized therapeutic antibodies, and has good neutralization activities, can recognize spatial epitopes of EV71-VP1 protein, and has broad-spectrum neutralization effect.
Smart Images

Figure CN114989294B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biotechnology and relates to an anti-EV71 virus antibody and a preparation method and application thereof. Background Art
[0002] Enterovirus 71 (EV71) is a single-stranded positive-strand non-enveloped RNA virus belonging to the Picornaviridae family and the Enterovirus A genus. Hand, foot, mouth disease (HFMD) is an infectious disease in children caused by a variety of enteroviruses. Children under 3 years old are susceptible to it. EV71 is one of the important pathogens causing HFMD. Adults can also be infected, but most of them are latent infections with no obvious clinical symptoms. EV71 is mainly transmitted through contact with the saliva, herpes fluid, feces of children with the disease, as well as food and objects contaminated by it.
[0003] Three EV71 inactivated vaccines have been approved for marketing in my country, and hand, foot and mouth disease has been brought under control to a certain extent. However, inactivated vaccines have certain side effects, such as fever and allergies in a small number of recipients. At the same time, the changes in neutralizing antibodies in the body and their protective effects on the body after emergency vaccination are still unclear. Therefore, it is particularly important to develop therapeutic neutralizing antibodies to deal with EV71 infection.
[0004] At present, related studies have identified multiple linear neutralizing antibody epitopes by synthesizing peptides targeting EV71 VP1 to immunize mice, but no spatial epitopes have been found. For example, CN102702351A discloses a human anti-EV71 virus neutralizing antibody EV71FabL6 obtained by screening using phage surface display technology. This antibody can specifically recognize EV71 virus particle antigens, can undergo significant enzyme-linked immunosorbent assay with EV71 virus, and has neutralizing activity against EV71 virus infection.
[0005] In summary, the development of different types of anti-EV71 virus antibodies is of great significance for further research on the disease mechanism of EV71 virus infection and the formulation of prevention and control strategies. Summary of the invention
[0006] In view of the deficiencies in the prior art and actual needs, the present invention provides an anti-EV71 virus antibody and a preparation method and application thereof. The present invention screens and obtains an anti-EV71 virus antibody with good specificity, and is an antibody against the spatial epitope of the EV71 virus VP1 protein.
[0007] To achieve the above object, the present invention adopts the following technical solutions:
[0008] In the first aspect, the present invention provides an anti-EV71 virus antibody, wherein the amino acid sequences of CDR1, CDR2 and CDR3 of the heavy chain of the anti-EV71 virus antibody include the sequences shown in SEQ ID NO.1, SEQ ID NO.2 and SEQ ID NO.3, respectively, and the amino acid sequences of CDR1, CDR2 and CDR3 of the light chain of the antibody include the sequences shown in SEQ ID NO.4, SEQ ID NO.5 and SEQ ID NO.6, respectively.
[0009] In the present invention, anti-EV71 virus antibodies with good specificity were screened, which are spatial epitope antibodies against EV71 virus VP1 protein and have good neutralizing activity, providing a scientific basis for the research of EV71-specific antiviral drugs and laying a foundation for the research of humanized therapeutic antibodies.
[0010] Preferably, the amino acid sequence of the variable region of the heavy chain of the anti-EV71 virus antibody includes the sequence shown in SEQ ID NO.7, and the amino acid sequence of the variable region of the light chain of the anti-EV71 virus antibody includes the sequence shown in SEQ ID NO.8.
[0011] SEQ ID NO.1: SFVMS.
[0012] SEQ ID NO. 2: SITGGGSVYYPDSVKG.
[0013] SEQ ID NO. 3: QGTAYDLWFAY.
[0014] SEQ ID NO.4:RASKSVSTSGYSYMH.
[0015] SEQ ID NO.5: LVSNLES.
[0016] SEQ ID NO.6: QHIR.
[0017] SEQ ID NO.7:
[0018] EVQLLETGGGLVKPGGSLKLSCAASGFTFSSFVMSWGRQTPDKSLEWVASITGGGSVYYPDSVKGRFTISRDTAGNILYLQMSSLRSEDTAMYYCARQGTAYDLWFAYWGQGTLVTVSA.
[0019] SEQ ID NO.8:
[0020] DIVMSQSPASLAVSLGQRATISYRASKSVSTSGYSYMHWNQQKPGQPPRLLIYLVSNLESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCQHIRELTRSEGGPSWK.
[0021] In a second aspect, the present invention provides a nucleic acid molecule comprising a nucleic acid sequence encoding the anti-EV71 virus antibody described in the first aspect.
[0022] Preferably, the nucleic acid sequence encoding the variable region of the heavy chain of the anti-EV71 virus antibody includes the sequence shown in SEQ ID NO.9, and the nucleic acid sequence encoding the variable region of the light chain of the anti-EV71 virus antibody includes the sequence shown in SEQ ID NO.10.
[0023] SEQ ID NO.9:
[0024] gaagtgcagctgttggagactgggggaggcttagtgaagcctggagggtccctgaaactctcctgtgcagcctctggattcactttcagtagttttgtcatgtcttggggtcgccagactccagataagagtctggagtgggtcgcatccattactggaggtggtagtgtatattatcc agacagtgtgaagggccgattcaccatctccagagatactgccgggaacatcctgtacctgcagatgagcagtctgaggtctgaggacacggccatgtattactgtgcaagacaaggaacggcgtatgacctctggtttgcttactggggccaagggactctggtcactgtctctgca.
[0025] SEQ ID NO.10:
[0026] gacattgtgatgtcacagtctcctgcttccttagctgtatctctggggcagagggccaccatctcatacagggccagcaaaagtgtcagtacatctggctatagttatatgcactggaaccaacagaaaccaggacagccacccagactcctcatctatcttgta tccaacctagaatctggggtccctgccaggttcagtggcagtgggtctgggacagacttcaccctcaacatccatcctgtggaggaggaggatgctgcaacctattactgtcagcacattagggagcttacacgttcggaggggggaccaagctggaaataaaa.
[0027] In a third aspect, the present invention provides a recombinant vector, wherein the recombinant vector contains the nucleic acid molecule described in the second aspect.
[0028] In a fourth aspect, the present invention provides a recombinant cell, wherein the recombinant cell contains a nucleic acid sequence encoding the anti-EV71 virus antibody described in the first aspect.
[0029] In a fifth aspect, the present invention provides a method for preparing the anti-EV71 virus antibody as described in the first aspect, the preparation method comprising:
[0030] The nucleic acid sequence encoding the anti-EV71 virus antibody described in the first aspect is inserted into an expression vector to obtain a recombinant vector, and the recombinant vector is introduced into a host cell for culture and purification to obtain the anti-EV71 virus antibody.
[0031] In a sixth aspect, the present invention provides the use of the anti-EV71 virus antibody as described in the first aspect in the preparation of an EV71 virus detection product.
[0032] The anti-EV71 virus antibody of the present invention has good specificity, specifically binds to the EV71 virus, and can be used for the detection of the EV71 virus, such as in ELISA detection.
[0033] In a seventh aspect, the present invention provides a reagent for detecting EV71 virus, wherein the reagent for detecting EV71 virus comprises the anti-EV71 virus antibody described in the first aspect.
[0034] In an eighth aspect, the present invention provides a pharmaceutical composition, comprising the anti-EV71 virus antibody described in the first aspect, the nucleic acid molecule described in the second aspect, the recombinant vector described in the third aspect, or the recombinant cell described in the fourth aspect.
[0035] Preferably, the pharmaceutical composition further comprises excipients.
[0036] Preferably, the excipients include any one or a combination of at least two of pharmaceutically acceptable carriers, diluents, excipients, fillers, binders, wetting agents, disintegrants, emulsifiers, cosolvents, solubilizers, osmotic pressure regulators, surfactants, coating materials, colorants, pH regulators, antioxidants, antibacterial agents or buffers.
[0037] In the ninth aspect, the present invention provides the use of the anti-EV71 virus antibody described in the first aspect, the nucleic acid molecule described in the second aspect, the recombinant vector described in the third aspect, the recombinant cell described in the fourth aspect or the pharmaceutical composition described in the eighth aspect in the preparation of drugs for preventing and / or treating diseases caused by EV71 virus.
[0038] Preferably, the disease comprises hand, foot and mouth disease.
[0039] The anti-EV71 virus antibody of the present invention has good neutralizing activity against different strains of EV71 virus, can recognize the spatial epitope of EV71-VP1 protein, and has a broad-spectrum neutralizing effect, which provides a scientific basis for the research of EV71-specific antiviral drugs and lays a foundation for the research of humanized therapeutic antibodies.
[0040] Compared with the prior art, the present invention has the following beneficial effects:
[0041] In the present invention, anti-EV71 virus antibodies with good specificity were screened out. They are spatial epitope antibodies against the EV71 virus VP1 protein, have good neutralizing activity, can be applied to the detection of EV71, and provide a scientific basis for the research of EV71-specific antiviral drugs, which is of great significance for further research on the disease mechanism of EV71 virus infection and the formulation of prevention and control strategies. BRIEF DESCRIPTION OF THE DRAWINGS
[0042] Figure 1 This is the electron microscopic image of purified EV71-VLPs;
[0043] Figure 2 This is the result of immunofluorescence detection of anti-EV71 virus antibodies. DETAILED DESCRIPTION
[0044] To further illustrate the technical means and effects of the present invention, the present invention is further described below in conjunction with the embodiments and drawings. It should be understood that the specific implementation methods described herein are only used to explain the present invention, rather than to limit the present invention.
[0045] If no specific techniques or conditions are specified in the examples, the techniques or conditions described in the literature in the field or the product instructions are used. If no manufacturer is specified for the reagents or instruments used, they are all conventional products that can be purchased through regular channels.
[0046] Example 1
[0047] In this example, EV71 virus particles (EV71-VLPs) were prepared.
[0048] (1) Construction of Ac-P1-3CD and Ac-VP1 recombinant baculovirus.
[0049] The P1 and 3CD genes of EV71 virus (Genebank: JQ804832) were inserted into the multiple cloning site region of the pFastBacDual vector with promoters of Polyhedrin and P10, respectively, to obtain the donor plasmid pFastBac-P1-3CD. The VP1 gene of EV71 virus was inserted into the multiple cloning site of the pFastBacI vector to obtain the donor plasmid pFastBac-VP1. Using the Bac-to-Bac system, the two donor plasmids were transferred to the DH10Bac competent medium, and the correct AcBac-P1-3CD and AcBac-VP1 were obtained using the blue-white screening technology. On this basis, the two donor plasmids were transfected into Sf9 cells, respectively, to obtain the Ac-P1-3CD and Ac-VP1 recombinant baculoviruses.
[0050] (2) Large-scale expression and preparation of EV71-VLPs
[0051] Sf9 cells were cultured in large quantities using a bioreactor (BC-7L, Guangzhou Qizhi Co., Ltd.) until the cell density reached 5×10 6 After 10 cells / ml, Ac-P1-3CD recombinant baculovirus was added at a dose of MOI=5, and the infected supernatant and cells were collected respectively after 72 hours.
[0052] (3) Purification of EV71-VLPs
[0053] Sf9 cells infected with Ac-P1-3CD for 72 hours were collected by centrifugation at 5000 rpm for 10 minutes, the cell pellet was resuspended with PBS, and the cells were broken with a high-pressure crusher. The broken cells were then centrifuged at 9000×g for 30 minutes, the supernatant was taken, and placed in an ultrafiltration device, ultrafiltered overnight with a 300 kD filter membrane, and the ultrafiltered sample was taken and purified using a liquid chromatograph (GE, AKTA-FPLC900) and a Sephacryl S200 gel column (GE), and the sample was collected according to the peak time.
[0054] (4) Electron microscopic observation of EV71-VLPs
[0055] Take 10 μL of purified EV71-VLPs sample, place it on a copper grid, allow it to adsorb for 2 minutes, then stain it with phosphotungstic acid for 1 minute. After it is naturally air-dried, the morphology of EV71-VLPs is observed under an electron microscope.
[0056] After EV71-VLPs were prepared in large quantities by the baculovirus expression system and purified, EV71-VLPs of uniform size and about 30 nm in diameter were observed under an electron microscope. Figure 1 shown.
[0057] Example 2
[0058] This example screens and identifies anti-EV71 virus antibodies.
[0059] (1) Animal immunization
[0060] After the EV71-VLPs purified in Example 1 were fully emulsified with an equal volume of Freund's adjuvant, 6-8 week old SPF female BALB / c mice (purchased from Hubei Provincial Center for Disease Control and Prevention) were immunized three times by intraperitoneal and subcutaneous injections. Each immunization was two weeks apart, the immunization dose was 100 μg / mouse, and a total of 5 mice were immunized. Orbital blood was collected before each immunization for subsequent testing.
[0061] (2) Cell fusion and hybridoma cell screening
[0062] After boosting immunization, BALB / c mice were killed by removing their eyeballs and drawing blood. The spleens of the mice were aseptically removed and ground in a sterile homogenizer containing 10 mL of RPMI-1640 medium. After standing for 10 min, the ground supernatant was taken and centrifuged at 1000 rpm for 10 min. The supernatant was discarded and the precipitate was resuspended in 10 mL of medium as immune spleen cell suspension for later use. 1×10 8 immune splenocytes and 2×10 7 After mixing the myeloma cells, centrifuge at 1000rpm for 10min, discard the supernatant, slowly add 1mL of preheated PEG to the centrifuge tube containing the cell mixture in a 37°C water bath, mix while adding, and then add preheated RPMI-1640 culture medium to 10mL. After mixing, centrifuge at 1000rpm for 5min, discard the supernatant, and then resuspend the cells in 50mL of HAT culture medium, inoculate in a 96-well plate, 100μL per well, and place the culture plate in a 37°C, 5% CO2 cell culture incubator for 8d.
[0063] When large colonies appear in the cell wells, cells in different wells are selected and diluted with HT medium, and transferred to a new 96-well plate to make the cells in the wells single cells. When large colonies appear in the cell wells again, the cell supernatant is taken for immunofluorescence detection. The specific steps are described in (4) below. The positive wells are taken for the next round of screening. After three rounds of screening, the positive monoclonal cells are expanded and cultured and numbered 22E7.
[0064] (3) Western blotting analysis of monoclonal antibodies (WB)
[0065] RD cells infected with EV71 virus for 18 h and Sf9 cells infected with Ac-P1-3CD and Ac-VP1 were taken for SDS-PAGE analysis and Western blot identification (refer to Bio-Rad operating instructions and Laemmli method). RD cells and Sf9 cells were taken as negative controls, and the screened cell lines were used as primary antibodies and HRP-labeled 1:1000 diluted goat anti-mouse IgG was used as secondary antibodies for detection. GE Image Quant LAS 4000 instrument (GE Healthcare, UK) was used for imaging.
[0066] (4) Indirect immunofluorescence assay (IFA) of monoclonal antibodies
[0067] After Ac-VP1 recombinant baculovirus infected Sf9 cells for 48 hours, the supernatant was discarded, and 300 μL of 4% paraformaldehyde was added to each well for fixation for 15 minutes. Healthy Sf9 cells were set as the blank control group. After 15 minutes, PBS was washed three times, and 100 μL of 0.5% Triton X-100 was immediately added for permeabilization for 10 minutes. After washing three times with PBS, 300 μL of 5% BSA was added to each well for blocking, and the cells were incubated at 37°C for 2 hours. After discarding the blocking solution, the antibodies produced by the screened positive cell lines were used as primary antibodies, and the cells were incubated at 37°C for 2 hours. After washing three times with PBS, 1:1000 diluted FITC-labeled goat anti-mouse was used as secondary antibody, and the cells were incubated at 37°C for 1 hour. Finally, PBS was washed three times, and 100 μL of PBS was added to each well for observation under a fluorescence microscope.
[0068] The cells infected with Ac-EV71-VP1 recombinant baculovirus for 48 hours were identified by immunofluorescence using positive monoclonal cell lines. Figure 2 As shown, the screened 22E7 monoclonal antibody can recognize EV71 structural protein VP1. In addition, no obvious bands appeared in the protein immunoblotting analysis, indicating that the 22E7 monoclonal antibody can recognize the spatial epitope of EV71-VP1 but cannot recognize the linear epitope of EV71 protein.
[0069] (5) Monoclonal antibody variable region sequence determination
[0070] Place the cell culture flask on ice, discard the supernatant, add 1 mL of QIXzol reagent (NZK-R15008), lyse at room temperature for 8 minutes, gently blow, and aspirate the liquid into the EP tube. Extract the total RNA of the positive monoclonal antibody cell line 22E7 according to the QIXzol reagent instructions. After the extraction, measure the RNA concentration and purity with a UV spectrophotometer. Take 4 μg RNA, add 10 mM dNTPMix, Oligo (dT) (500 μg / mL), 5X First-Strand Buffer, 0.1 M DTT, RNaseOUT TM Recombinant Ribonuclease Inhibitor and M-MLV RT were used to reverse transcribe and synthesize cDNA. Flash MasterMix, P510-AA) was used to amplify the target gene fragment. The primer sequences are shown in Table 1. PCR reaction conditions: 98°C pre-denaturation for 30 seconds, 98°C for 10 seconds, 55°C for 5 seconds, 72°C for 5 seconds, for a total of 30 cycles, and finally 72°C for 1 minute for complete extension. 40 μL of PCR product was taken for nucleic acid electrophoresis using 1% agarose gel electrophoresis.
[0071] Table 1
[0072]
[0073]
[0074] Purify PCR products with a band size of about 300 bp according to the Gel Extraction Kit instructions. Connect the variable region target genes of the light and heavy chains to the pTOPO-Blunt vector according to the Zero Background pTOPO-Blunt Cloning Kit instructions, construct recombinants, thaw the competent DH10B recipient bacteria on ice, add 2 μL of the constructed recombinants for electroporation, add the prepared SOC, 37°C, 250 rpm, 1 hour, then spread on the LB plate (containing 100 μg / ml Amp), and culture at 37°C overnight. The next day, use a sterile pipette tip to pick 10 light and heavy chain monoclonal colonies from the plate and place them in 1 mL of LB medium containing 50 μg / mL Amp. After culturing at 37°C, 250 rpm for 10 hours, send the bacterial solution to first-generation sequencing. The sequencing primers use universal primers M13F and M13R.
[0075] The light chain and heavy chain variable regions of the screened monoclonal antibodies were sequenced. The amino acid sequences of CDR1, CDR2 and CDR3 of the heavy chain of the monoclonal antibody of the cell line 22E7 were shown in SEQ ID NO.1, SEQ ID NO.2 and SEQ ID NO.3, respectively, and the amino acid sequences of CDR1, CDR2 and CDR3 of the light chain were shown in SEQ ID NO.4, SEQ ID NO.5 and SEQ ID NO.6, respectively. The amino acid sequence of the heavy chain variable region was SEQ ID NO.7, and the corresponding nucleic acid sequence was SEQ ID NO.9. The amino acid sequence of the light chain variable region was SEQ ID NO.8, and the corresponding nucleic acid sequence was SEQ ID NO.10.
[0076] Example 3
[0077] This example measures the neutralizing titer of the screened monoclonal antibodies.
[0078] The neutralization titer of the screened monoclonal cell line 22E7 was determined. The EV71-xf strain (Genebank: JQ804832) was selected for the test. The monoclonal antibody was first diluted to a concentration gradient of 0.4 μg / mL, 0.7 μg / mL, 1.4 μg / mL, 2.8 μg / mL, 5.6 μg / mL, 11.3 μg / mL, 22.5 μg / mL, 45 μg / mL, 90 μg / mL and 180 μg / mL, and then the EV71 virus was diluted to 100 TCID 50 , and then mixed with equal volumes of diluted monoclonal antibodies, incubated at 37°C, infected RD cells after 2 hours, observed cytopathic effect after 3 days, and calculated the neutralization titer. The results are shown in Table 2, where "√" indicates no cytopathic effect and neutralizing activity, and "-" indicates cytopathic effect and no neutralizing activity. The results show that the anti-EV71 virus antibody of the present invention has good neutralizing activity against the EV71-xf strain.
[0079] Table 2
[0080]
[0081] In summary, the anti-EV71 virus antibodies screened by the present invention can recognize the spatial epitope of EV71-VP1 protein, but cannot recognize the linear epitope, and have a good neutralizing effect on EV71-xf strain, which provides a scientific basis for the research of EV71-specific antiviral drugs, lays a foundation for the research of humanized therapeutic antibodies, and is of great significance for further research on the disease mechanism of EV71 virus infection and the formulation of prevention and control strategies.
[0082] The applicant declares that the present invention illustrates the detailed method of the present invention through the above-mentioned embodiments, but the present invention is not limited to the above-mentioned detailed method, that is, it does not mean that the present invention must rely on the above-mentioned detailed method to be implemented. Those skilled in the art should understand that any improvement of the present invention, equivalent replacement of various raw materials of the product of the present invention, addition of auxiliary components, selection of specific methods, etc., all fall within the protection scope and disclosure scope of the present invention. Sequence Listing <110> Wuhan Institute of Virology, Chinese Academy of Sciences <120> Anti-EV71 virus antibody and preparation method and application thereof <130> 2022-05-25 <160> 10 <170> PatentIn version 3.3 <210> 1 <211> 5 <212> PRT <213> Artificial sequence <400> 1 Ser Phe Val Met Ser 1 5 <210> 2 <211> 16 <212> PRT <213> Artificial sequence <400> 2 Ser Ile Thr Gly Gly Gly Ser Val Tyr Tyr Pro Asp Ser Val Lys Gly 1 5 10 15 <210> 3 <211> 11 <212> PRT <213> Artificial sequence <400> 3 Gln Gly Thr Ala Tyr Asp Leu Trp Phe Ala Tyr 1 5 10 <210> 4 <211> 15 <212> PRT <213> Artificial sequence <400> 4 Arg Ala Ser Lys Ser Val Ser Thr Ser Gly Tyr Ser Tyr Met His 1 5 10 15 <210> 5 <211> 7 <212> PRT <213> artificial sequence <400> 5 Leu Val Ser Asn Leu Glu Ser 1 5 <210> 6 <211> 4 <212> PRT <213> artificial sequence <400> 6 Gln His Ile Arg 1 <210> 7 <211> 119 <212> PRT <213> artificial sequence <400> 7 Glu Val Gln Leu Leu Glu Thr Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe 20 25 30 Val Met Ser Trp Gly Arg Gln Thr Pro Asp Lys Ser Leu Glu Trp Val 35 40 45 Ala Ser Ile Thr Gly Gly Gly Ser Val Tyr Tyr Pro Asp Ser Val Lys 50 55 60 Gly Arg Phe Thr Ile Ser Arg Asp Thr Ala Gly Asn Ile Leu Tyr Leu 65 70 75 80 Gln Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys Ala 85 90 95 Arg Gln Gly Thr Ala Tyr Asp Leu Trp Phe Ala Tyr Trp Gly Gln Gly 100 105 110 Thr Leu Val Thr Val Ser Ala 115 <210> 8 <211> 108 <212> PRT <213> Artificial Sequence <400> 8 Asp Ile Val Met Ser Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly 1 5 10 15 Gln Arg Ala Thr Ile Ser Tyr Arg Ala Ser Lys Ser Val Ser Thr Ser 20 25 30 Gly Tyr Ser Tyr Met His Trp Asn Gln Gln Lys Pro Gly Gln Pro Pro 35 40 45 Arg Leu Leu Ile Tyr Leu Val Ser Asn Leu Glu Ser Gly Val Pro Ala 50 55 60 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His 65 70 75 80 Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys Gln His Ile Arg 85 90 95 Glu Leu Thr Arg Ser Glu Gly Gly Pro Ser Trp Lys 100 105 <210> 9 <211> 357 <212> DNA <213> Artificial sequence <400> 9 gaagtgcagc tgttggagac tgggggaggc ttagtgaagc ctggagggtc cctgaaactc 60 tcctgtgcag cctctggatt cactttcagt agttttgtca tgtcttgggg tcgccagact 120 ccagataaga gtctggagtg ggtcgcatcc attactggag gtggtagtgt atattatcca 180 gacagtgtga agggccgatt caccatctcc agagatactg ccgggaacat cctgtacctg 240 cagatgagca gtctgaggtc tgaggacacg gccatgtatt actgtgcaag acaaggaacg 300 gcgtatgacc tctggtttgc ttactggggc caagggactc tggtcactgt ctctgca 357 <210> 10 <211> 329 <212> DNA <213> Artificial sequence <400> 10 gacattgtga tgtcacagtc tcctgcttcc ttagctgtat ctctggggca gagggccacc 60 atctcataca gggccagcaa aagtgtcagt acatctggct atagttatat gcactggaac 120 caacagaaac caggacagcc acccagactc ctcatctatc ttgtatccaa cctagaatct 180 ggggtccctg ccaggttcag tggcagtggg tctgggacag acttcaccct caacatccat 240 cctgtggagg aggaggatgc tgcaacctat tactgtcagc acattaggga gcttacacgt 300 tcggaggggg gaccaagctg gaaataaaa 329
Claims
1. An anti-EV71 virus antibody, characterized in that: The amino acid sequences of CDR1, CDR2 and CDR3 of the heavy chain of the anti-EV71 virus antibody are the sequences shown in SEQ ID NO.1, SEQ ID NO.2 and SEQ ID NO.3, respectively, and the amino acid sequences of CDR1, CDR2 and CDR3 of the light chain of the antibody are the sequences shown in SEQ ID NO.4, SEQ ID NO.5 and SEQ ID NO.6, respectively.
2. The anti-EV71 virus antibody according to claim 1, characterized in that: The amino acid sequence of the variable region of the heavy chain of the anti-EV71 virus antibody is shown in SEQ ID NO.7, and the amino acid sequence of the variable region of the light chain of the anti-EV71 virus antibody is shown in SEQ ID NO.
8.
3. A nucleic acid molecule, characterized in that The nucleic acid molecule contains a nucleic acid sequence encoding the anti-EV71 virus antibody according to claim 1 or 2.
4. A recombinant vector, characterized in that: The recombinant vector contains the nucleic acid molecule according to claim 3.
5. A recombinant cell, characterized in that The recombinant cell contains a nucleic acid sequence encoding the anti-EV71 virus antibody according to claim 1 or 2.
6. The method for preparing an anti-EV71 virus antibody according to claim 1 or 2, characterized in that: The preparation method comprises: Insert the nucleic acid sequence encoding the anti-EV71 virus antibody according to claim 1 or 2 into an expression vector to obtain a recombinant vector, introduce the recombinant vector into a host cell for culture, and purify to obtain the anti-EV71 virus antibody.
7. Use of the anti-EV71 virus antibody according to claim 1 or 2 in the preparation of EV71 virus detection products.
8. A reagent for detecting EV71 virus, characterized in that: The reagent for detecting EV71 virus includes the anti-EV71 virus antibody according to claim 1 or 2.
9. A pharmaceutical composition, characterized in that The pharmaceutical composition comprises the anti-EV71 virus antibody according to claim 1 or 2, the nucleic acid molecule according to claim 3, the recombinant vector according to claim 4 or the recombinant cell according to claim 5.
10. The pharmaceutical composition according to claim 9, characterized in that The pharmaceutical composition further comprises excipients.
11. The pharmaceutical composition according to claim 10, characterized in that The excipients include any one or a combination of at least two of pharmaceutically acceptable carriers, diluents, excipients, fillers, binders, wetting agents, disintegrants, emulsifiers, cosolvents, solubilizers, osmotic pressure regulators, surfactants, coating materials, colorants, pH regulators, antioxidants, antibacterial agents or buffers.
12. Use of the anti-EV71 antibody according to claim 1 or 2, the nucleic acid molecule according to claim 3, the recombinant vector according to claim 4, the recombinant cell according to claim 5 or the pharmaceutical composition according to any one of claims 9 to 11 in the preparation of a drug for preventing and / or treating a disease caused by EV71 virus, characterized in that: The disease is hand, foot and mouth disease.
